Roughly half as many patients with cirrhosis in remission from overt hepatic encephalopathy (OHE) experienced a breakthrough ...

Rifaximin has already been successfully used in adults with SIBO and IBS. Aim: To assess the SIBO prevalence and symptoms improvement in IBS children after treatment with Rifaximin. Study design ...

For patients with a history of overt hepatic encephalopathy (OHE), rifaximin monotherapy (MT) results in significantly fewer ...

Rifaximin is a minimally absorbed antibiotic that is FDA-approved for treatment of travelers' diarrhea and prevention of hepatic encephalopathy. The primary endpoint (patient-reported "adequate ...

The antibiotic, rifaximin, has enabled the global emergence of vancomycin-resistant enterococcus faecium, or VRE, a superbug that frequently causes serious infections in hospitalised patients ...

For patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement, rifaximin used before and after the procedure is associated with a reduced risk for overt ...

But when exposed to rifaximin, the VRE bacteria don't just get one boost – they gain multiple abilities, like super-speed and super-strength, allowing them to easily defeat even the final boss ...

(NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an analysis of Xifaxan® (rifaximin) monotherapy will be presented during a ...

A common antibiotic used to treat liver disease could give rise to an “almost untreatable” superbug, scientists warned in a new study. The antibiotic, rifaximin, has enabled the global emergence of ...

A new study has found that an antibiotic for liver disease patients could expose them to greater risk of a dangerous superbug. The international team of researchers found that an antibiotic ...